On January 11, 2026 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported preliminary, unaudited results for the quarter and full year ended December 31, 2025.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Fourth quarter 2025 preliminary unaudited financial results
For the three-month period ended December 31, 2025, as compared to the same period of 2024:
Total revenue of approximately $280 million, an increase of 39%
Reported approximately 79,000 oncology tests, an increase of 38%
Reported approximately 38,000 Shield screening tests, compared to 6,400 tests in the prior year period
Full year 2025 preliminary unaudited financial results
For the twelve-month period ended December 31, 2025, as compared to the same period of 2024:
Total revenue of approximately $981 million, an increase of 33%
Reported approximately 276,000 oncology tests, an increase of 34%
Reported approximately 87,000 Shield screening tests
"2025 was a breakout year for Guardant, with total revenue growth accelerating to 33% year-over-year," said Helmy Eltoukhy, co-founder and co-CEO. "We saw exceptional volume growth in Oncology over the last year, primarily driven by pioneering innovation from our Smart Platform and best-in-class commercial execution. We expect this momentum to continue throughout the year with the launch of multiple groundbreaking products that will fuel the next phase of growth in our Oncology business."
"We are incredibly proud of Shield’s strong momentum as we continue to strengthen our leadership in the blood-based colorectal cancer screening market, with Shield positioned as one of the most successful diagnostic launches to date," said AmirAli Talasaz, co-founder and co-CEO. "Since FDA approval, nearly 100,000 patients have been screened with Shield. We have now expanded Shield to include multi-cancer detection findings, further enhancing the clinical value of the platform for both patients and physicians. Together, these milestones will further advance the fight against cancer in 2026 and beyond."
Preliminary unaudited free cash flow was approximately negative $54 million for the fourth quarter of 2025, and approximately negative $233 million for the full year 2025. Cash, cash equivalents, restricted cash, and marketable debt securities were approximately $1.3 billion as of December 31, 2025.
Guardant Health has not completed preparation of its financial statements for the fourth quarter or full year of 2025. The revenue, test volumes and free cash flow presented in this release for the fourth quarter and the year ended December 31, 2025, are preliminary and unaudited and are thus inherently uncertain and subject to change as we complete our financial results. The company is in the process of completing its customary year-end close and review procedures as of and for the year ended December 31, 2025, and there can be no assurance that final results for this period will not differ from these estimates. During the preparation of Guardant Health’s consolidated financial statements and related notes as of and for the year ended December 31, 2025, the company’s independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary financial estimates presented herein.
Upcoming events
Guardant Health plans to report its fourth quarter and full year audited financial results for the period ended December 31, 2025, during its February 2026 earnings call.
(Press release, Guardant Health, JAN 11, 2026, View Source [SID1234661928])